Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response

BACKGROUND The serotonin transporter is the molecular target of many antidepressants, and the gene (SLC6A4) encoding this protein has been associated with response to selective serotonin reuptake inhibitors (SSRIs). We sought to test further the hypothesis that SLC6A4 is associated with SSRI response by resequencing this gene in subjects with major depression. METHODS The sequence of all exons, parts of all introns, and the promoter region containing a polymorphic repeat polymorphism (HTTLPR) previously associated with SSRI response was determined for 96 subjects, and variants were tested for association to treatment response with fluoxetine. RESULTS We screened a total of 712 kilobases of sequence and found 27 SLC6A4 variants, 21 of which were previously undescribed. Seventeen were seen on one chromosome each, including three of the five exonic variants. One polymorphism (rs25531), just upstream of the HTTLPR, showed evidence of an association with treatment response, and biochemical experiments showed this polymorphism altered binding of nuclear extracts to a consensus sequence for the activator protein 2 transcription factor, which is believed to be a critical factor in regulating neural gene expression in mammals. CONCLUSIONS These results support an association between response to SSRIs and deoxyribonucleic acid variation at the serotonin transporter locus. We have also identified a potentially important functional variant that contributes to this association and a possible biologic mechanism that could mediate its effect.

[1]  R. Blakely,et al.  Alternative Splicing of the Human Serotonin Transporter Gene , 1997, Journal of neurochemistry.

[2]  P. Zwanzger,et al.  Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression , 2001, Neuroscience Letters.

[3]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[4]  R. Tjian,et al.  Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis. , 1991, Genes & development.

[5]  Michael F Egan,et al.  A susceptibility gene for affective disorders and the response of the human amygdala. , 2005, Archives of general psychiatry.

[6]  H. Tanabe,et al.  The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants , 2000, Molecular Psychiatry.

[7]  F. Dudbridge.  Pedigree disequilibrium tests for multilocus haplotypes , 2003, Genetic epidemiology.

[8]  Joseph L. Gastwirth,et al.  Trend Tests for Case-Control Studies of Genetic Markers: Power, Sample Size and Robustness , 2002, Human Heredity.

[9]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[10]  A. Serretti,et al.  The pharmacogenomics of selective serotonin reuptake inhibitors , 2004, The Pharmacogenomics Journal.

[11]  P J McGrath,et al.  Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. , 2000, The Journal of clinical psychiatry.

[12]  L. Oreland,et al.  Chronic citalopram treatment induces time-dependent changes in the expression and DNA-binding activity of transcription factor AP-2 in rat brain , 2003, European Neuropsychopharmacology.

[13]  Andreas Heinz,et al.  A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity , 2000, Biological Psychiatry.

[14]  Stephen A. Krawetz,et al.  Bioinformatics Methods and Protocols , 1999 .

[15]  Anil K Malhotra,et al.  Pharmacogenetics of psychotropic drug response. , 2004, The American journal of psychiatry.

[16]  S. Gabriel,et al.  Assessing the impact of population stratification on genetic association studies , 2004, Nature Genetics.

[17]  Kurt Hornik,et al.  No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism , 2001, Biological Psychiatry.

[18]  J. Amsterdam,et al.  Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. , 1998, Archives of general psychiatry.

[19]  L. Oreland,et al.  Chronic pharmacological treatment with certain antidepressants alters the expression and DNA-binding activity of transcription factor AP-2. , 2000, Life sciences.

[20]  J. Knowles,et al.  Investigation of serotonin-related genes in antidepressant response , 2004, Molecular Psychiatry.

[21]  B. Pollock,et al.  Serotonin Transporter Promoter Polymorphism in African Americans , 2003 .

[22]  N. Freimer,et al.  Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes , 2001, Nature Genetics.

[23]  A. Serretti,et al.  From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes , 2004, Psychopharmacology.

[24]  B. Lerer,et al.  Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. , 2002, The international journal of neuropsychopharmacology.

[25]  F. Quitkin,et al.  Placebos, drug effects, and study design: a clinician's guide. , 1999, The American journal of psychiatry.

[26]  L. Wasserman,et al.  Genomic control, a new approach to genetic-based association studies. , 2001, Theoretical population biology.

[27]  K. Itoh,et al.  Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[28]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[29]  J. Harro,et al.  Levels of transcription factors AP-2α and AP-2β in the brainstem are correlated to monoamine turnover in the rat forebrain , 2001, Neuroscience Letters.

[30]  K. Roeder,et al.  The power of genomic control. , 2000, American journal of human genetics.

[31]  B. Carroll,et al.  Serotonin transporter gene polymorphism and antidepressant response , 2000, Neuroreport.

[32]  Marc Laruelle,et al.  Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. , 2004, The American journal of psychiatry.

[33]  Stephen J. Guter,et al.  Transmission disequilibrium mapping at the serotonin transporter gene (SLC6A4) region in autistic disorder , 2002, Molecular Psychiatry.

[34]  A. Caspi,et al.  Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.

[35]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[36]  B. Pollock,et al.  Meta-analysis of serotonin transporter polymorphisms and affective disorders , 2004, Psychiatric genetics.

[37]  M. Thase,et al.  Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors , 2001, British Journal of Psychiatry.